Progress of chronic myeloid leukemia
10.3760/cma.j.cn115356-20211231-00317
- VernacularTitle:慢性粒细胞白血病研究进展
- Author:
Chenxing ZHAO
1
;
Jianda HU
Author Information
1. 福建医科大学附属协和医院血液科 福建省血液病学重点实验室 福建省血液病研究所，福州 350001
- Keywords:
Leukemia, myeloid, chronic;
Tyrosine kinase inhibitor;
Discontinuation
- From:
Journal of Leukemia & Lymphoma
2022;31(3):133-136
- CountryChina
- Language:Chinese
-
Abstract:
In the tyrosine kinase inhibitor (TKI) therapy era, patients with chronic myeloid leukemia (CML) have embarked on the trend of "chronic disease management". With the advent of 4 generations TKI drugs, there remain unmet needs for optimal CML treatment, such as treatment-free remission and disease recurrence after discontinuation. This article reviews the research progress of CML at the 63rd American Society of Hematology annual meeting.
